Veru Inc. delivered a robust performance in Q1 FY2026, marked by significant progress in its clinical trials and regulatory developments for its obesity treatment candidates, Novosarm and cabozantinib.
- The Phase 2b clinical trial for Novosarm demonstrated proof of concept for selective fat loss while preserving lean mass in older patients, a critical advancement in obesity treatment.
- Regulatory discussions with the FDA confirmed two potential pathways for approval, enhancing the strategic outlook for Novosarm in combination with GLP-1 receptor agonists.
- The FDA's recent acknowledgment of bone mineral density as a validated surrogate endpoint could open new opportunities for Novosarm’s development in postmenopausal women with obesity and osteoporosis.
- Veru continues to address challenges in GLP-1 treatments, with Novosarm potentially providing solutions for patients who experience weight loss plateaus on current therapies.
Community Discussion